Tag Archive for: biotech

iOnctura Announces Publication Of Pioneering Research Describing The Unique Biological Features Of Roginolisib

/in

Preclinical Data On Roginolisib, An Oral First-In-Class Non-ATP Competitive Allosteric Modulator Of PI3Kδ, For The Potential Treatment Of Solid And Hematological Tumors Geneva, Switzerland and Amsterdam, The Netherlands, 16 March – iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, today announces the publication of non-clinical research on roginolisib in the […]

Read more

Positive phase 2 data from Atrial Fibrillation clinical trial – primary endpoint met

/in

First-in-class SK channel inhibition proof of mechanism achieved First new approach to treating Atrial Fibrillation for 20 years Copenhagen, Denmark – Acesion Pharma (“Acesion”), the biotech pioneering first-in-class novel therapies for Atrial Fibrillation (“AF”), the most common cardiac arrhythmia, today announced positive data from its Phase 2 trial of AP30663, a first-in-class SK ion channel […]

Read more

Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases

/in

Financing co-led by Sunstone Life Science Ventures and Sound Bioventures with participation from Industrifonden, Innovestor’s Life Science Fund and P53 Invest Discovery of a novel mechanism with the potential to prevent the death of neurons in neurodegenerative diseases First-in-Class, lead drug candidate advances into clinical development in a Phase 1b study Aarhus, Denmark March 14th, […]

Read more

Leucid Bio provides business update and outlook for 2023

/in

Proprietary Lateral CAR Platform achieved pre-clinical proof-of-concept data demonstrating prolonged disease-free survival compared to other CAR T-cell products. Lead programme, LEU011 has completed pre-clinical development for the treatment of solid tumours and is in pre-clinical development for a range of haematological malignancies. Leucid expects to file its CTA to initiate the clinical trial in H1 […]

Read more

Ariceum Therapeutics Appoints Radioligand Expert, Germo Gericke, M.D., as Chief Medical Officer

/in

Dr. Gericke brings extensive experience in the research and development of radioligand therapies Appointment coincides with launch of Ariceum International AG in Basel, Switzerland Berlin, Germany, 1 February 2023 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, is pleased to announce […]

Read more